In Q2 2023, Foresite Capital held 6 positions worth $174.1M. They exited 3. Their largest holding was PHVS ($56.7M). Portfolio value grew +31.6% versus the prior quarter.
Frequently asked questions
What stocks did Foresite Capital own in Q2 2023?
Foresite Capital held 6 biotech stocks in their 13F portfolio in Q2 2023. Their top positions include PHVS, LYEL, ACRS, KURA, CBAY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Foresite Capital's portfolio worth in Q2 2023?
Foresite Capital's tracked biotech portfolio was worth $174.1M across 6 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Foresite Capital buy in Q2 2023?
Foresite Capital did not initiate any new positions in Q2 2023, but increased 1 existing holding.
What did Foresite Capital sell in Q2 2023?
Foresite Capital fully exited 3 positions in Q2 2023, including QSIAW, ASND, NTRA. They also trimmed 1 existing positions.
Is Foresite Capital a biotech fund?
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.
Want AI analysis, insider signals, and catalyst overlays for Foresite Capital?
View latest Foresite Capitalportfolio →